If you follow weight loss news, you have probably seen the headlines. A new injection producing weight loss numbers that rival bariatric surgery. That drug is retatrutide, and the results coming out of its clinical trials are genuinely remarkable.

But there is important context those headlines often skip, and if you are considering your options, you need the full picture. This guide explains retatrutide weight loss in plain language: what the drug is, how it works, what the research actually shows, and its current availability, straight from our doctor-led team at Zorah Med Spa.

What Is Retatrutide?

Retatrutide is an experimental weight loss medication being developed by Eli Lilly, the same company behind tirzepatide. Like the GLP-1 injections already on the market, it is designed to reduce appetite and support significant weight loss.

What sets it apart is how many hormone pathways it targets.

Semaglutide targets one hormone pathway. Tirzepatide targets two. Retatrutide targets three: GLP-1, GIP, and glucagon. Because of this, researchers often call it a “triple agonist.”

That third pathway, glucagon, is the key difference. In addition to curbing appetite like the other medications, glucagon activity may help increase energy expenditure and influence how the body burns fat. This triple-action design is why retatrutide has generated so much excitement in obesity medicine.

How Does Retatrutide Work?

To understand retatrutide, it helps to understand the medications that came before it.

GLP-1 and GIP are hormones your body naturally releases after eating. They signal fullness to your brain, slow down digestion, and help regulate blood sugar. Medications that mimic these hormones make you feel satisfied with less food, which is why they have transformed weight loss treatment.

Retatrutide does all of that, then adds glucagon into the mix. Glucagon is best known for its role in blood sugar, but it also appears to boost the body’s metabolic rate and support fat breakdown. By activating all three pathways at once, retatrutide aims to attack weight from multiple angles simultaneously.

In theory, that means more appetite control and a metabolic boost working together. The trial data suggests the theory is holding up.

What Do the Retatrutide Trial Results Show?

This is where retatrutide earns its reputation. The retatrutide weight loss numbers from its Phase 3 program are among the strongest ever recorded for any weight loss medication.

In the large TRIUMPH-1 trial, which followed more than 2,000 adults with obesity over 80 weeks, participants on the highest dose lost an average of roughly 28 percent of their body weight. For someone starting at 250 pounds, that is around 70 pounds. Nearly half of those patients lost at least 30 percent of their body weight, a threshold previously associated mainly with weight loss surgery.

To put that in perspective, here is how the leading injections compare in their respective trials:

Those figures explain the buzz. If retatrutide performs this way across its full trial program, it could become one of the most effective obesity medications ever developed.

Retatrutide vs Tirzepatide: What Is the Difference?

Since both come from Eli Lilly, this is one of the most common questions we hear.

The core difference is that extra hormone pathway. Tirzepatide works on two receptors and produces average weight loss around 20 percent. Retatrutide adds glucagon activity on top, pushing average results closer to 28 percent in trials.

But there is a crucial distinction that matters more than the numbers. Tirzepatide is FDA-approved and available today through doctor-supervised programs. Retatrutide is not. It remains investigational.

That means for anyone who wants to start medical weight loss now, tirzepatide is a proven, available option, while retatrutide is still a work in progress.

Is Retatrutide FDA-Approved? What You Need to Know

Here is the part the headlines often leave out, and it matters for your safety.

As of 2026, retatrutide is not FDA-approved. It is still in Phase 3 clinical trials, the final stage of testing before a company can apply for approval. Based on the trial timeline, industry observers expect Eli Lilly to file for FDA approval in late 2026, with a potential market launch not until 2027 or 2028.

Until then, the only legal and safe way to access retatrutide is by enrolling in an official clinical trial. It cannot be legally prescribed, filled at a pharmacy, or sold online.

This is important because retatrutide is being marketed illegally by some online sellers and unregulated sources. Any product sold as retatrutide outside of a clinical trial is not FDA-reviewed, and its purity, dosing, and safety cannot be verified. Using these products carries real health risks. If you want to explore legitimate access, ClinicalTrials.gov is the official government database where you can search for enrolling studies.

We are keeping a close eye on retatrutide’s progress. The moment it earns FDA approval and can be offered safely and legally, it may become part of our medical weight loss program. Until that day, we focus on the proven options available now. You can also read more about the treatment on our retatrutide information page.

What Are the Potential Side Effects?

Because retatrutide works on the same core pathways as semaglutide and tirzepatide, its side effect profile looks similar in trials. The most common are digestive:

• Nausea, especially early in treatment
• Constipation or diarrhea
• Reduced appetite
• Mild fatigue

As with the other GLP-1 medications, these tend to be most noticeable when starting or increasing the dose and often ease as the body adjusts. Trial researchers have also been monitoring other effects, which is exactly the kind of long-term safety information the FDA review process is designed to confirm before a drug reaches the public.

This is the entire reason FDA approval matters. It ensures a medication has been thoroughly vetted for safety, effectiveness, dosing, and manufacturing quality before anyone takes it outside a controlled study.

Your Proven Options Available Right Now

Retatrutide is exciting, but you do not have to wait for the future to start losing weight. The medications available today are highly effective and, crucially, FDA-approved and doctor-supervised.

At Zorah Med Spa in Des Plaines, our current weight loss programs feature:

• Semaglutide: The most widely used weight loss medication in the country, with average weight loss around 15 percent of body weight and over a decade of research behind it.
• Tirzepatide: The advanced dual-action option, with average weight loss around 20 percent, ideal for those with more weight to lose.

Both are offered through flat monthly memberships that include your medication, supportive peptide and Lipo+ treatments, and ongoing care from our medical team. No guesswork, no unregulated products, no waiting on a future approval.

The Bottom Line on Retatrutide Weight Loss

Retatrutide represents the next generation of weight loss treatment, and its triple-agonist design is producing some of the most impressive results the field has ever seen. It is a genuine reason for optimism.

But optimism should not override safety. Until retatrutide completes its trials and earns FDA approval, the smart, safe move is to work with proven medications under real medical supervision, not to chase an unapproved drug from an unregulated source.

If you are ready to start losing weight now with a doctor-led program, we can help. Schedule a consultation online or call Zorah Med Spa at (708) 412-4040, and our medical team will help you find the right option for your goals today, while we keep watching for what is coming next.

Frequently Asked Questions

Can I get retatrutide right now?

Not through a pharmacy or clinic. As of 2026, retatrutide is not FDA-approved and is only legally available by enrolling in a clinical trial. Any online seller offering it is not providing a legitimate, regulated product.

Is retatrutide better than tirzepatide?

In clinical trials, retatrutide produced greater average weight loss, around 28 percent versus about 20 percent for tirzepatide. However, tirzepatide is FDA-approved and available now, while retatrutide is still investigational.

When will retatrutide be available?

Based on current trial timelines, Eli Lilly is expected to seek FDA approval in late 2026, with a possible market launch in 2027 or 2028. Timelines can change depending on trial results and regulatory review.

Is it safe to buy retatrutide online?

No. Products sold as retatrutide online are not FDA-reviewed, and their purity, dosing, and safety cannot be verified. This carries real health risks. The only safe access is through an official clinical trial.

What can I take instead while I wait?

FDA-approved options like semaglutide and tirzepatide are highly effective and available now through doctor-supervised programs. Many patients start with these and reassess as new medications become available.